Given that oxaliplatin constitute one of the most used drugs in the treatment of CRCs, it is important to evaluate its effects with respect to the Hippo pathway and to YAP/TAZ which can elicit conflicting roles to oppose or promote CRC tumorigenesis. This evidence concerns the gene YAP1 and colorectal carcinoma.